Arthritis & Rheumatism

Number of times cited: 239

• Richard A. Furie, Daniel J. Wallace, Cynthia Aranow, James Fettiplace, Barbara Wilson, Prafull Mistry, David A. Roth and David Gordon, Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus, Arthritis & Rheumatology, 70, 6, (868-877), (2018).
  Wiley Online Library
• Hannah A. Blair and Sean T. Duggan, Belimumab: A Review in Systemic Lupus Erythematosus, Drugs, (2018).
  Crossref
• A. Doria, W. Stohl, A. Schwarting, M. Okada, M. Scheinberg, R. Vollenhoven, A. E. Hammer, J. Groark, D. Bass, N. L. Fox, D. Roth and D. Gordon, Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus, Arthritis & Rheumatology, 70, 8, (1256-1264), (2018).
  Wiley Online Library
• Jessica K. Gordon, Viktor Martyanov, Jennifer M. Franks, Elana J. Bernstein, Jackie Szymonifka, Cynthia Magro, Horatio F. Wildman, Tammara A. Wood, Michael L. Whitfield and Robert F. Spiera, Belimumab for the Treatment of Early Diffuse Systemic Sclerosis, Arthritis & Rheumatology, 70, 2, (308-316), (2017).
  Wiley Online Library
• Siddiq Anwar and M Yousuf Karim, Update on systemic vasculitides, Journal of Clinical Pathology, 10.1136/jclinpath-2016-203875, 70, 6, (476-482), (2017).
  Crossref
• Eileen Samy, Stephen Wax, Bertrand Huard, Henry Hess and Pascal Schneider, Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases, International Reviews of Immunology, 10.1080/08830185.2016.1276903, 36, 1, (3-19), (2017).
  Crossref
• Sebastian Volc, Kamran Ghoreschi and Hui Shen, Immunotherapy, Practical Immunodermatology, 10.1007/978-94-024-0902-4_15, (367-381), (2016).
  Crossref
• W Chatham, A Chadha, J Fettiplace, C Kleoudis, D Bass, D Roth and D Gordon, A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus, Lupus, 10.1177/0961203317703495, 26, 14, (1483-1490), (2017).
  Crossref
• A.L. Kimzey, M-S Piche, M Wood, AB. Weir and J Lansita, Immunophenotyping in Drug Development, Reference Module in Biomedical Sciences, 10.1016/B978-0-12-801238-3.64236-8, (2017).
  Crossref
• William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Andrea Doria, Anne E. Hammer, Christi Kleoudis, James Groark, Damon Bass, Norma Lynn Fox, David Roth and David Gordon, Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study, Arthritis & Rheumatology, 69, 5, (1016-1027), (2017).
  Wiley Online Library
• William Stohl, The Future of B-cell Activating Factor Antagonists in the Treatment of Systemic Lupus Erythematosus, Journal of Rheumatic Diseases, 10.4078/jrd.2017.24.2.65, 24, 2, (65), (2017).
  Crossref
• Sara Guerreiro Castro and David A. Isenberg, Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X17690474, 9, 3, (75-85), (2017).
  Crossref
• William Stohl, Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE), Expert Review of Clinical Immunology, 10.1080/1744666X.2017.1291343, 13, 6, (623-633), (2017).
  Crossref
• Y. J. Poh, B. Baptista and David P. D’Cruz, Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration, Expert Review of Clinical Immunology, 10.1080/1744666X.2017.1371592, 13, 10, (925-938), (2017).
  Crossref
• Zahi Touma, Amyn Sayani, Christian A. Pineau, Isabelle Fortin, Mark Matsos, George A. Ecker, Andrew Chow and Sandra Iczkovitz, Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study, Rheumatology International, 10.1007/s00296-017-3682-9, 37, 6, (865-873), (2017).
  Crossref
• Ioannis Parodis, Christopher Sjöwall, Andreas Jönsen, Daniel Ramsköld, Agneta Zickert, Martina Frodlund, Azita Sohrabian, Laurent Arnaud, Johan Rönnelid, Vivianne Malmström, Anders A. Bengtsson and Iva Gunnarsson, Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus, Autoimmunity Reviews, 10.1016/j.autrev.2017.02.005, 16, 4, (343-351), (2017).
  Crossref
• Xianjuan Shen, Yuehua Guo, Jing Qi, Wei Shi, Xinhua Wu and Shaoqing Ju, Binding of B‐cell maturation antigen to B‐cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways, Cell Biochemistry and Function, 34, 2, (104-110), (2016).
  Wiley Online Library
• A. M. Nicoletti, C. H. Kenny, A. M. Khalil, Q. Pan, K. L. M. Ralph, J. Ritchie, S. Venkataramani, D. H. Presky, S. M. DeWire and S. R. Brodeur, Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.116.236075, 359, 1, (37-44), (2016).
  Crossref
• Sonali Narain and Richard Furie, Update on clinical trials in systemic lupus erythematosus, Current Opinion in Rheumatology, 10.1097/BOR.0000000000000311, 28, 5, (477-487), (2016).
  Crossref
• Melody Y. Hu, Panos Stathopoulos, Kevin C. O’connor, Sean J. Pittock and Richard J. Nowak, Current and future immunotherapy targets in autoimmune neurology, Autoimmune Neurology, 10.1016/B978-0-444-63432-0.00027-X, (511-536), (2016).
  Crossref
• Andreas Schwarting, Johann O. Schroeder, Tobias Alexander, Marc Schmalzing, Christoph Fiehn, Christof Specker, Alessandra Perna, Constanze Cholmakow-Bodechtel, Volker B. Koscielny and Heike Carnarius, First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study, Rheumatology and Therapy, 10.1007/s40744-016-0047-x, 3, 2, (271-290), (2016).
  Crossref
• Manzoor M. Khan, Monoclonal Antibodies as Therapeutic Agents, Immunopharmacology, 10.1007/978-3-319-30273-7_5, (157-196), (2016).
  Crossref
• S Elizabeth Franks, Andrew Getahun, P Mark Hogarth and John C Cambier, Targeting B cells in treatment of autoimmunity, Current Opinion in Immunology, 10.1016/j.coi.2016.09.003, 43, (39-45), (2016).
  Crossref
• Herbert Struemper, Thomas Murtaugh, Jane Gilbert, Matthew E. Barton, Joseph Fire, James Groark, Norma Lynn Fox, David Roth and David Gordon, Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects, Clinical Pharmacology in Drug Development, 5, 3, (208-215), (2015).
  Wiley Online Library
• D A Roth, A Thompson, Y Tang, A E Hammer, C T Molta and D Gordon, Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab, Lupus, 10.1177/0961203315604909, 25, 4, (346-354), (2015).
  Crossref
• James W Swann and Oliver A Garden, Novel immunotherapies for immune-mediated haemolytic anaemia in dogs and people, The Veterinary Journal, 10.1016/j.tvjl.2015.10.022, 207, (13-19), (2016).
  Crossref
• Weiliang Zhuang, Jianjun Zhang, Lili Pei, Shuping Fang, Honghao Liu, Ruixue Wang and Yunpeng Su, Generation and characterization of human B lymphocyte stimulator blocking monoclonal antibody, Molecular Immunology, 10.1016/j.molimm.2016.08.002, 77, (141-147), (2016).
  Crossref
• M. Govoni, A. Bortoluzzi, M. Padovan, E. Silvagni, M. Borrelli, F. Donelli, S. Ceruti and F. Trotta, The diagnosis and clinical management of the neuropsychiatric manifestations of lupus, Journal of Autoimmunity, 10.1016/j.jaut.2016.06.013, 74, (41-72), (2016).
  Crossref
• André Frenzel, Thomas Schirrmann and Michael Hust, Phage display-derived human antibodies in clinical development and therapy, mAbs, 10.1080/19420862.2016.1212149, 8, 7, (1177-1194), (2016).
  Crossref
• Fabio Enrique Ospina, Juan Felipe Betancur, Juan Pablo Suso, Evelyn Muñoz-Buitron, Carlos Alberto Cañas and Gabriel J. Tobón, Role of the cytokine BAFF in autoimmune diseases: Physiopathology and therapeutic targets, Revista Colombiana de Reumatología (English Edition), 10.1016/j.rcreue.2016.11.003, 23, 3, (177-194), (2016).
  Crossref
• A Schwarting, M A Dooley, D A Roth, L Edwards, A Thompson and B Wilson, Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus, Lupus, 10.1177/0961203316655215, 25, 14, (1587-1596), (2016).
  Crossref
• Wendy J. Komocsar, Jamie L. Blackbourne, Carolyn A. Halstead, Colleen J. Winstead and Daniel Wierda, Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey ( Macaca fasicularis ): A summary of three pre-clinical immunotoxicology evaluations , Journal of Immunotoxicology, 10.3109/1547691X.2014.994793, 13, 1, (7-19), (2015).
  Crossref
• William Stohl and Agnes Banfalvi, B cell-independent contribution of BAFF to murine autoimmune disease, Clinical Immunology, 10.1016/j.clim.2016.07.009, 172, (111-116), (2016).
  Crossref
• Fabio Enrique Ospina, Juan Felipe Betancur, Juan Pablo Suso, Evelyn Muñoz-Buitron, Carlos Alberto Cañas and Gabriel J. Tobón, Papel de la citocina BAFF en las enfermedades autoinmunes: rol fisiopatológico y estrategias terapéuticas, Revista Colombiana de Reumatología, 10.1016/j.rcreu.2016.06.003, 23, 3, (177-194), (2016).
  Crossref
• Morton A. Scheinberg, Colin M. Hislop and Renee S. Martin, Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser, Expert Opinion on Biological Therapy, 10.1517/14712598.2016.1169270, 16, 5, (723-733), (2016).
  Crossref
• Achilleas Floudas, Sylvie Amu and Padraic G. Fallon, New Insights into IL-10 Dependent and IL-10 Independent Mechanisms of Regulatory B Cell Immune Suppression, Journal of Clinical Immunology, 10.1007/s10875-016-0263-8, 36, S1, (25-33), (2016).
  Crossref
• Norman T. Ilowite and Ronald M. Laxer, Pharmacology, Textbook of Pediatric Rheumatology, 10.1016/B978-0-323-24145-8.00013-2, (161-175.e6), (2016).
  Crossref
• Julien Häsler, Martin F. Flajnik, Gareth Williams, Frank S. Walsh and J.Lynn Rutkowski, VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry, Molecular Immunology, 10.1016/j.molimm.2016.05.009, 75, (28-37), (2016).
  Crossref
• Yu Zhou and James D. Marks, Mechanism of Action for Therapeutic Antibodies, Biosimilars of Monoclonal Antibodies, (85-111), (2016).
  Wiley Online Library
• Ronald F. van Vollenhoven, Michelle Petri, Daniel J. Wallace, David A. Roth, Charles T. Molta, Anne E. Hammer, Yongqiang Tang and April Thompson, Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials, Arthritis & Rheumatology, 68, 9, (2184-2192), (2016).
  Wiley Online Library
• Kobra Omidfar and Maryam Daneshpour, Advances in phage display technology for drug discovery, Expert Opinion on Drug Discovery, 10.1517/17460441.2015.1037738, 10, 6, (651-669), (2015).
  Crossref
• William Stohl, Joan T. Merrill, R. John Looney, Jill Buyon, Daniel J. Wallace, Michael H. Weisman, Ellen M. Ginzler, Blaire Cooke, Donna Holloway, Arunan Kaliyaperumal, Kameswara Rao Kuchimanchi, Tsui Chern Cheah, Erik Rasmussen, John Ferbas, Shelley S. Belouski, Wayne Tsuji and Debra J. Zack, Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials, Arthritis Research & Therapy, 10.1186/s13075-015-0741-z, 17, 1, (2015).
  Crossref
• Richard Furie, Kiley Toder and Ekaterini Zapantis, Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis, Seminars in Nephrology, 10.1016/j.semnephrol.2015.08.012, 35, 5, (509-520), (2015).
  Crossref
• Claire Dobson, Ralph Minter and Celia Hart-Shorrock, Naive Antibody Libraries from Natural Repertoires, Phage Display In Biotechnology and Drug Discovery, Second Edition, 10.1201/b18196-18, (455-494), (2015).
  Crossref
• Sandra A. Morais, Andreia Vilas-Boas and David A. Isenberg, B-cell survival factors in autoimmune rheumatic disorders, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X15586782, 7, 4, (122-151), (2015).
  Crossref
• Jonas Kügler, Sonja Wilke, Doris Meier, Florian Tomszak, André Frenzel, Thomas Schirrmann, Stefan Dübel, Henk Garritsen, Björn Hock, Lars Toleikis, Mark Schütte and Michael Hust, Generation and analysis of the improved human HAL9/10 antibody phage display libraries, BMC Biotechnology, 10.1186/s12896-015-0125-0, 15, 1, (10), (2015).
  Crossref
• Xuehua Ke, Debra F. Eisenberg Lawrence, Alan Oglesby, Jeetvan Patel, Hong Kan and Robert Boggs, A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings, Clinical Therapeutics, 10.1016/j.clinthera.2015.10.008, 37, 12, (2852-2863), (2015).
  Crossref
• Joyce S. Hui-Yuen, Xiao Q. Li and Anca D. Askanase, Belimumab in systemic lupus erythematosus: a perspective review, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X15588514, 7, 4, (115-121), (2015).
  Crossref
• Phillip A. Doerfler, Sushrusha Nayak, Roland W. Herzog, Laurence Morel and Barry J. Byrne, BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease, Clinical Immunology, 10.1016/j.clim.2015.03.022, 158, 2, (140-147), (2015).
  Crossref
• Fang Wei, Yan Chang and Wei Wei, The role of BAFF in the progression of rheumatoid arthritis, Cytokine, 10.1016/j.cyto.2015.07.014, 76, 2, (537-544), (2015).
  Crossref
• M. D. Sanchez-Nino and A. Ortiz, 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians, Nephrology Dialysis Transplantation, 10.1093/ndt/gfu213, 30, 3, (394-400), (2014).
  Crossref
• I. Parodis, A. Zickert, B. Sundelin, M. Axelsson, J. Gerhardsson, E. Svenungsson, V. Malmstrom and I. Gunnarsson, Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy, Lupus Science & Medicine, 10.1136/lupus-2014-000061, 2, 1, (e000061-e000061), (2015).
  Crossref
• Y. Shida, N. Takahashi, T. Sakamoto, H. Ino, A. Endo and T. Hirama, The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers, Journal of Clinical Pharmacy and Therapeutics, 39, 1, (97-101), (2013).
  Wiley Online Library
• William Stohl, Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus, Expert Opinion on Therapeutic Targets, 10.1517/14728222.2014.888415, 18, 4, (473-489), (2014).
  Crossref
• Anca D. Askanase, Jinoos Yazdany and Charles T. Molta, Post-marketing Experiences with Belimumab in the Treatment of SLE Patients, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2014.04.007, 40, 3, (507-517), (2014).
  Crossref
• Giacomo Emmi, Elena Silvestri, Danilo Squatrito, Mario Milco D’Elios, Lucia Ciucciarelli, Domenico Prisco and Lorenzo Emmi, Behçet’s syndrome pathophysiology and potential therapeutic targets, Internal and Emergency Medicine, 10.1007/s11739-013-1036-5, 9, 3, (257-265), (2014).
  Crossref
• Laura Runkel and Jennifer Stacey, Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?, Expert Opinion on Biological Therapy, 10.1517/14712598.2014.884065, 14, 4, (491-501), (2014).
  Crossref
• Chi Chiu Mok, Update on B-cell targeted therapies for systemic lupus erythematosus, Expert Opinion on Biological Therapy, 10.1517/14712598.2014.895810, 14, 6, (773-788), (2014).
  Crossref
• Zozik Fattah and David A Isenberg, Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies, Expert Opinion on Biological Therapy, 10.1517/14712598.2014.871256, 14, 3, (311-326), (2014).
  Crossref
• Andrew E Nixon, Daniel J Sexton and Robert C Ladner, Drugs derived from phage display, mAbs, 10.4161/mabs.27240, 6, 1, (73-85), (2013).
  Crossref
• Gang Xin, Yun Su, Kang-Sheng Li, Min Chen, Ming-Hui Zhao and Li-Xia Xu, Serum B-cell Activating Factor in Myecloperoxiase-antineutrophil Cytoplasmic Antibodies-associated Vasculitis, The American Journal of the Medical Sciences, 10.1097/MAJ.0b013e3182a55ab6, 348, 1, (25-29), (2014).
  Crossref
• Vibeke Strand, Roger A Levy, Ricard Cervera, Michelle A Petri, Helen Birch, William W Freimuth, Z John Zhong and Ann E Clarke, Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials, Annals of the Rheumatic Diseases, 10.1136/annrheumdis-2012-202865, 73, 5, (838-844), (2013).
  Crossref
• Ronald F. van Vollenhoven, Ioannis Parodis and Adrian Levitsky, Biologics in SLE: Towards new approaches, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2013.07.006, 27, 3, (341-349), (2013).
  Crossref
• I Parodis, M Axelsson and I Gunnarsson, Belimumab for systemic lupus erythematosus: a practice-based view, Lupus, 10.1177/0961203313476154, 22, 4, (372-380), (2013).
  Crossref
• Giulio Fortuna and Michael T. Brennan, Systemic Lupus Erythematosus, Dental Clinics of North America, 10.1016/j.cden.2013.06.003, 57, 4, (631-655), (2013).
  Crossref
• Sonia Berrih-Aknin, Samia Ragheb, Rozen Le Panse and Robert P. Lisak, Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis, Autoimmunity Reviews, 10.1016/j.autrev.2013.03.011, 12, 9, (885-893), (2013).
  Crossref
• Jaime Calvo-Alén, Lucía Silva-Fernández, Eduardo Úcar-Angulo, José María Pego-Reigosa, Alejandro Olivé, Carmen Martínez-Fernández, Víctor Martínez-Taboada, José Luis Marenco, Estíbaliz Loza, Javier López-Longo, Juan Jesús Gómez-Reino, María Galindo-Izquierdo, Antonio Fernández-Nebro, María José Cuadrado, María Ángeles Aguirre-Zamorano, Antonio Zea-Mendoza and Íñigo Rúa-Figueroa, Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico, Reumatología Clínica, 10.1016/j.reuma.2013.04.001, 9, 5, (281-296), (2013).
  Crossref
• Herbert Struemper, Cecil Chen and Wendy Cai, Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus, The Journal of Clinical Pharmacology, 53, 7, (711-720), (2013).
  Wiley Online Library
• RR Minter, ES Cohen, B Wang, M Liang, I Vainshtein, G Rees, L Eghobamien, P Harrison, DA Sims, C Matthews, T Wilkinson, P Monk, C Drinkwater, L Fabri, A Nash, M McCourt, L Jermutus, L Roskos, IK Anderson and MA Sleeman, Protein engineering and preclinical development of a GM‐CSF receptor antibody for the treatment of rheumatoid arthritis, British Journal of Pharmacology, 168, 1, (200-211), (2012).
  Wiley Online Library
• Moncef Zouali and Eugene A. Uy, Belimumab Therapy in Systemic Lupus Erythematosus, BioDrugs, 10.1007/s40259-013-0031-8, 27, 3, (225-235), (2013).
  Crossref
• Lukas Bossaller and Achim Rothe, Monoclonal antibody treatments for rheumatoid arthritis, Expert Opinion on Biological Therapy, 10.1517/14712598.2013.811230, 13, 9, (1257-1272), (2013).
  Crossref
• Xin-guang Liu and Ming Hou, Immune Thrombocytopenia and B-Cell-Activating Factor/A Proliferation-Inducing Ligand, Seminars in Hematology, 10.1053/j.seminhematol.2013.03.021, 50, (S89-S99), (2013).
  Crossref
• Zahi Touma, Murray B Urowitz and Dafna D Gladman, Systemic lupus erythematosus: an update on current pharmacotherapy and future directions, Expert Opinion on Biological Therapy, 10.1517/14712598.2013.764411, 13, 5, (723-737), (2013).
  Crossref
• Xiaolei Ma, Nan Che, Zhifeng Gu, Jing Huang, Dandan Wang, Jun Liang, Yayi Hou, Gary Gilkeson, Liwei Lu and Lingyun Sun, Allogenic Mesenchymal Stem Cell Transplantation Ameliorates Nephritis in Lupus Mice via Inhibition of B-Cell Activation, Cell Transplantation, 10.3727/096368912X658692, 22, 12, (2279-2290), (2013).
  Crossref
• Jaime Calvo-Alén, Lucía Silva-Fernández, Eduardo Úcar-Angulo, José María Pego-Reigosa, Alejandro Olivé, Carmen Martínez-Fernández, Víctor Martínez-Taboada, José Luis Marenco, Estíbaliz Loza, Javier López-Longo, Juan Jesús Gómez-Reino, María Galindo-Izquierdo, Antonio Fernández-Nebro, María José Cuadrado, María Ángeles Aguirre-Zamorano, Antonio Zea-Mendoza and Íñigo Rúa-Figueroa, SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus, Reumatología Clínica (English Edition), 10.1016/j.reumae.2013.07.001, 9, 5, (281-296), (2013).
  Crossref
• Ronald F. van Vollenhoven, Novel Therapies for SLE, Dubois' Lupus Erythematosus and Related Syndromes, 10.1016/B978-1-4377-1893-5.00053-4, (640-647), (2013).
  Crossref
• Xingzhong Jin and Changhai Ding, Belimumab – an anti-BLyS human monoclonal antibody for rheumatoid arthritis, Expert Opinion on Biological Therapy, 10.1517/14712598.2012.758248, 13, 2, (315-322), (2012).
  Crossref
• Gaurav Malviya, Simonetta Salemi, Bruno Laganà, Andrea Picchianti Diamanti, Raffaele D’Amelio and Alberto Signore, Biological Therapies for Rheumatoid Arthritis: Progress to Date, BioDrugs, 10.1007/s40259-013-0021-x, 27, 4, (329-345), (2013).
  Crossref
• R. Fischer-Betz and M. Schneider, Empfehlungen zum Einsatz von Belimumab beim systemischen Lupus erythematodesRecommendation for use of belimumab for systemic lupus erythematosus, Zeitschrift für Rheumatologie, 10.1007/s00393-013-1212-z, 72, 5, (462-467), (2013).
  Crossref
• Aris N. Economides and Neil Stahl, Receptor‐Fc and Ligand Traps as High‐Affinity Biological Blockers: Development and Clinical Applications, Fusion Protein Technologies for Biopharmaceuticals, (143-162), (2013).
  Wiley Online Library
• Kirsten Fairfax, Ian R. Mackay and Fabienne Mackay, BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus, IUBMB Life, 64, 7, (595-602), (2012).
  Wiley Online Library
• D. Yehudai, A. Snir, R. Peri, K. Halasz, T. Haj, M. Odeh and A. Kessel, B Cell‐Activating Factor Enhances Interleukin‐6 and Interleukin‐10 Production by ODN‐Activated Human B Cells, Scandinavian Journal of Immunology, 76, 4, (371-377), (2012).
  Wiley Online Library
• William Stohl, Falk Hiepe, Kevin M. Latinis, Mathew Thomas, Morton A. Scheinberg, Ann Clarke, Cynthia Aranow, Frank R. Wellborne, Carlos Abud‐Mendoza, Douglas R. Hough, Lilia Pineda, Thi‐Sau Migone, Z. John Zhong, William W. Freimuth and W. Winn Chatham, Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, Arthritis & Rheumatism, 64, 7, (2328-2337), (2012).
  Wiley Online Library
• Eric G. Boyce and Bryan E. Fusco, Belimumab: Review of Use in Systemic Lupus Erythematosus, Clinical Therapeutics, 10.1016/j.clinthera.2012.02.028, 34, 5, (1006-1022), (2012).
  Crossref
• William Stohl, Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?, Current Rheumatology Reports, 10.1007/s11926-012-0254-6, 14, 4, (303-309), (2012).
  Crossref
• Lesley J. Scott, Celeste B. Burness and Paul L. McCormack, Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus, BioDrugs, 10.2165/11209060-000000000-00000, 26, 3, (195-199), (2012).
  Crossref
• Koji KITAGORI and Daisuke KAWABATA, B cell abnormality in systemic lupus erythematosus, Japanese Journal of Clinical Immunology, 10.2177/jsci.35.495, 35, 6, (495-502), (2012).
  Crossref
• Joanne Bronson, Murali Dhar, William Ewing and Nils Lonberg, To Market, To Market—2011, Annual Reports in Medicinal Chemistry Volume 47, 10.1016/B978-0-12-396492-2.00031-X, (499-569), (2012).
  Crossref
• Jennifer L. Rogers, Donald S. Serafin, Roman G. Timoshchenko and Teresa K. Tarrant, Cellular Targeting in Autoimmunity, Current Allergy and Asthma Reports, 10.1007/s11882-012-0307-y, 12, 6, (495-510), (2012).
  Crossref
• Vera Gesheva, Zsuzsanna Szekeres, Nikolina Mihaylova, Iliyana Dimitrova, Maria Nikolova, Anna Erdei, Jozsef Prechl and Andrey Tchorbanov, Generation of Gene-Engineered Chimeric DNA Molecules for Specific Therapy of Autoimmune Diseases, Human Gene Therapy Methods, 10.1089/hgtb.2012.051, 23, 6, (357-365), (2012).
  Crossref
• Susan S. Kim, Kyriakos A. Kirou and Doruk Erkan, Belimumab in systemic lupus erythematosus: an update for clinicians, Therapeutic Advances in Chronic Disease, 10.1177/2040622311424806, 3, 1, (11-23), (2011).
  Crossref
• Ricard Cervera and Gerard Espinosa, Belimumab in SLE, Immunotherapeutic Agents for SLE, 10.2217/ebo.11.207, (42-54), (2012).
  Crossref
• Andrea González-Muñoz, Evert Bokma, Desmond O’Shea, Kevin Minton, Martin Strain, Katherine Vousden, Christine Rossant, Lutz Jermutus and Ralph Minter, Tailored amino acid diversity for the evolution of antibody affinity, mAbs, 10.4161/mabs.21728, 4, 6, (664-672), (2014).
  Crossref
• Alexis Boneparth and Anne Davidson, B-cell activating factor targeted therapy and lupus, Arthritis Research & Therapy, 10.1186/ar3920, 14, Suppl 4, (S2), (2012).
  Crossref
• Chang-Hee Suh, B Cell Targeted Therapy in Rheumatic Disease, Journal of Rheumatic Diseases, 10.4078/jrd.2012.19.2.67, 19, 2, (67), (2012).
  Crossref
• Fabien B Vincent, Eric F Morand and Fabienne Mackay, BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus, Immunology & Cell Biology, 90, 3, (293-303), (2012).
  Wiley Online Library
• Joan T. Merrill, Ellen M. Ginzler, Daniel J. Wallace, James D. McKay, Jeffrey R. Lisse, Cynthia Aranow, Frank R. Wellborne, Michael Burnette, John Condemi, Z. John Zhong, Lilia Pineda, Jerry Klein and William W. Freimuth, Long‐term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus, Arthritis & Rheumatism, 64, 10, (3364-3373), (2012).
  Wiley Online Library
• Robert P. Lisak and Samia Ragheb, The role of B cell–activating factor in autoimmune myasthenia gravis, Annals of the New York Academy of Sciences, 1274, 1, (60-67), (2012).
  Wiley Online Library
• Nikola S. Kerekov, Nikolina M. Mihaylova, Ivan Grozdev, Todor A. Todorov, Milena Nikolova, Marta Baleva, Maria Nikolova, Jozsef Prechl, Anna Erdei and Andrey I. Tchorbanov, Elimination of autoreactive B cells in humanized SCID mouse model of SLE, European Journal of Immunology, 41, 11, (3301-3311), (2011).
  Wiley Online Library
• Norman T. Ilowite and Ronald M. Laxer, PHARMACOLOGY AND DRUG THERAPY, Textbook of Pediatric Rheumatology, 10.1016/B978-1-4160-6581-4.10006-8, (71-126), (2011).
  Crossref
• Andrew C. Chan, B cell immunotherapy in autoimmunity – 2010 update, Molecular Immunology, 10.1016/j.molimm.2010.11.021, 48, 11, (1344-1347), (2011).
  Crossref
• Guillermo J. Pons-Estel, Rosa Serrano, Miguel A. Plasín, Gerard Espinosa and Ricard Cervera, Epidemiology and management of refractory lupus nephritis, Autoimmunity Reviews, 10.1016/j.autrev.2011.04.032, 10, 11, (655-663), (2011).
  Crossref
• Samia Ragheb and Robert P. Lisak, B-Cell-Activating Factor and Autoimmune Myasthenia Gravis, Autoimmune Diseases, 10.4061/2011/939520, 2011, (1-10), (2011).
  Crossref
• Andrew R M Bradbury, Sachdev Sidhu, Stefan Dübel and John McCafferty, Beyond natural antibodies: the power of in vitro display technologies, Nature Biotechnology, 10.1038/nbt.1791, 29, 3, (245-254), (2011).
  Crossref
• Ricard Cervera and Gerard Espinosa, Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus, Clinical Investigation, 10.4155/cli.11.140, 1, 11, (1555-1561), (2011).
  Crossref
• Achim Rothe and Andrea Rubbert, Recombinant proteins in rheumatology – recent advances, New Biotechnology, 10.1016/j.nbt.2011.03.019, 28, 5, (502-510), (2011).
  Crossref
• G. A. Lied and A. Berstad, Functional and Clinical Aspects of the B‐Cell‐Activating Factor (BAFF): A Narrative Review, Scandinavian Journal of Immunology, 73, 1, (1-7), (2010).
  Wiley Online Library
• Changhai Ding, Ran Li, Jianhua Xu, Flavia Cicuttini and Graeme Jones, Belimumab therapy for systemic lupus erythematosus and potential treatment of rheumatoid arthritis, Drug Development Research, 72, 7, (623-633), (2011).
  Wiley Online Library
• Chi Chiu Mok, Belimumab: the first US FDA approved biological therapy for systemic lupus erythematosus, International Journal of Clinical Rheumatology, 10.2217/ijr.11.33, 6, 4, (373-377), (2011).
  Crossref
• Jennifer Peregoy and Frances Vaughn Wilder, The effects of vitamin C supplementation on incident and progressive knee osteoarthritis: a longitudinal study, Public Health Nutrition, 10.1017/S1368980010001783, 14, 04, (709-715), (2010).
  Crossref
• Iñaki Sanz, Uma Yasothan and Peter Kirkpatrick, Belimumab, Nature Reviews Drug Discovery, 10.1038/nrd3436, 10, 5, (335-336), (2011).
  Crossref
• Celeste B. Burness and Paul L. McCormack, Belimumab, Drugs, 10.2165/11208440-000000000-00000, 71, 18, (2435-2444), (2011).
  Crossref
• Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, Stephen Hall, Roger A Levy, Renato E Jimenez, Edmund K-M Li, Mathew Thomas, Ho-Youn Kim, Manuel G León, Coman Tanasescu, Eugeny Nasonov, Joung-Liang Lan, Lilia Pineda, Z John Zhong, William Freimuth and Michelle A Petri, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, The Lancet, 10.1016/S0140-6736(10)61354-2, 377, 9767, (721-731), (2011).
  Crossref
• Bita Shakoory and Winn Clatham, Efficacy and Safety Data of Belimumab in Patients with Systemic Lupus Erythematosus, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X11407541, 3, 3, (159-164), (2011).
  Crossref
• Samar M. Fawzy, Tamer A. Gheita, Eman El-Nabarawy, Heba H. El-Demellawy and Olfat G. Shaker, Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus, The Egyptian Rheumatologist, 10.1016/j.ejr.2010.12.001, 33, 1, (45-51), (2011).
  Crossref
• Noam Jacob and William Stohl, Cytokine disturbances in systemic lupus erythematosus, Arthritis Research & Therapy, 10.1186/ar3349, 13, 4, (228), (2011).
  Crossref
• William Stohl, Jean L Scholz and Michael P Cancro, Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside, Current Opinion in Rheumatology, 10.1097/BOR.0b013e328344c15e, 23, 3, (305-310), (2011).
  Crossref
• Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J. Wallace, Dana Tegzová, Jorge Sanchez‐Guerrero, Andreas Schwarting, Joan T. Merrill, W. Winn Chatham, William Stohl, Ellen M. Ginzler, Douglas R. Hough, Z. John Zhong, William Freimuth and Ronald F. van Vollenhoven, A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis & Rheumatism, 63, 12, (3918-3930), (2011).
  Wiley Online Library
• Michael J. Townsend, John G. Monroe and Andrew C. Chan, B‐cell targeted therapies in human autoimmune diseases: an updated perspective, Immunological Reviews, 237, 1, (264-283), (2010).
  Wiley Online Library
• M. Grünke, H. Bastian, H. Schulze-Koops and G.-R. Burmester, Neue Biologika und oral verfügbare neue MedikamenteNew biologics and orally available compounds, Zeitschrift für Rheumatologie, 10.1007/s00393-009-0531-6, 69, 7, (626-632), (2010).
  Crossref
• A. L. Hepburn, S. Narat and J. C. Mason, The management of peripheral blood cytopenias in systemic lupus erythematosus, Rheumatology, 10.1093/rheumatology/keq269, 49, 12, (2243-2254), (2010).
  Crossref
• Susan Lee and Mark Ballow, Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2010.02.025, 125, 4, (814-820), (2010).
  Crossref
• Annett M. Jacobi, Weiqing Huang, Tao Wang, William Freimuth, Inaki Sanz, Richard Furie, Meggan Mackay, Cynthia Aranow, Betty Diamond and Anne Davidson, Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging study, Arthritis & Rheumatism, 62, 1, (201-210), (2009).
  Wiley Online Library
• Gabriel J Tobón, Alain Saraux, Jacques-Olivier Pers and Pierre Youinou, Emerging biotherapies for Sjögren's syndrome, Expert Opinion on Emerging Drugs, 10.1517/14728211003702392, 15, 2, (269-282), (2010).
  Crossref
• M. Hegazy, H. Darwish, H. Darweesh, A. El-Shehaby and Y. Emad, Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices, Clinical Immunology, 10.1016/j.clim.2009.12.012, 135, 1, (118-124), (2010).
  Crossref
• Amy K Wiglesworth, Kelly M Ennis and Denise R Kockler, Belimumab: A BLyS-Specific Inhibitor for Systemic Lupus Erythematosus, Annals of Pharmacotherapy, 10.1345/aph.1P360, 44, 12, (1955-1961), (2016).
  Crossref
• Santi Suryani and Stuart G Tangye, Therapeutic implications of advances in our understanding of transitional B-cell development in humans, Expert Review of Clinical Immunology, 10.1586/eci.10.55, 6, 5, (765-775), (2014).
  Crossref
• Noam Jacob and William Stohl, Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future, Autoimmunity, 10.3109/08916930903374600, 43, 1, (84-97), (2009).
  Crossref
• Avram Goldberg and Elena Katzap, Belimumab for the treatment of systemic lupus erythematosus, International Journal of Clinical Rheumatology, 10.2217/ijr.10.32, 5, 4, (407-413), (2010).
  Crossref
• Sarah G. Hymowitz and Ingrid E. Wertz, A20: from ubiquitin editing to tumour suppression, Nature Reviews Cancer, 10.1038/nrc2775, 10, 5, (332-341), (2010).
  Crossref
• A. Illes, L. Varoczy, G. Papp, P. C. Wilson, P. Alex, R. Jonsson, T. Kovacs, Y. T. Konttinen, M. Zeher, B. Nakken and P. Szodoray, Aspects of B‐Cell Non‐Hodgkin’s Lymphoma Development: A Transition from Immune‐Reactivity to Malignancy, Scandinavian Journal of Immunology, 69, 5, (387-400), (2009).
  Wiley Online Library
• Diana J. Auyeung-Kim, Madhav N. Devalaraja, Thi-Sau Migone, Wendy Cai and Gary J. Chellman, Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator, Reproductive Toxicology, 10.1016/j.reprotox.2009.07.002, 28, 4, (443-455), (2009).
  Crossref
• Meng Cao, Peng Cao, Huaijiang Yan, Wuguang Lu, Fang Ren, Yunlong Hu and Shuangquan Zhang, Construction, Purification, and Characterization of Anti-BAFF scFv–Fc Fusion Antibody Expressed in CHO/dhfr− Cells, Applied Biochemistry and Biotechnology, 10.1007/s12010-008-8434-6, 157, 3, (562-574), (2008).
  Crossref
• Daniel J. Wallace, William Stohl, Richard A. Furie, Jeffrey R. Lisse, James D. McKay, Joan T. Merrill, Michelle A. Petri, Ellen M. Ginzler, W. Winn Chatham, W. Joseph McCune, Vivian Fernandez, Marc R. Chevrier, Z. John Zhong and William W. Freimuth, A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus, Arthritis Care & Research, 61, 9, (1168-1178), (2009).
  Wiley Online Library
• Michael P. Cancro, David P. D’Cruz and Munther A. Khamashta, The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus, Journal of Clinical Investigation, 10.1172/JCI38010, 119, 5, (1066-1073), (2009).
  Crossref
• T. Menge, H.-C. Büdingen, M.C. Dalakas, B.C. Kieseier and H.-P. Hartung, B-Zell-gerichtete Multiple-Sklerose-TherapieTargeting B cells in multiple sclerosis, Der Nervenarzt, 10.1007/s00115-008-2664-2, 80, 2, (190-198), (2009).
  Crossref
• Capucine Daridon, Gerd R Burmester and Thomas Dörner, Anticytokine therapy impacting on B cells in autoimmune diseases, Current Opinion in Rheumatology, 10.1097/BOR.0b013e32832a0760, 21, 3, (205-210), (2009).
  Crossref
• William R. Gilliland, Michael P. Keith and Kathleen Uhl, SYSTEMIC LUPUS ERYTHEMATOSUS, Pharmacology and Therapeutics, 10.1016/B978-1-4160-3291-5.50080-9, (1047-1062), (2009).
  Crossref
• Angela Nagel, Michael Hertl and Rüdiger Eming, B-Cell-Directed Therapy for Inflammatory Skin Diseases, Journal of Investigative Dermatology, 10.1038/jid.2008.192, 129, 2, (289-301), (2009).
  Crossref
• Fabienne Mackay and Pascal Schneider, Cracking the BAFF code, Nature Reviews Immunology, 10.1038/nri2572, 9, 7, (491-502), (2009).
  Crossref
• Richard A. Furie, Michelle A. Petri, Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill, William Stohl, W. Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc R. Chevrier, Z. John Zhong and William W. Freimuth, Novel evidence‐based systemic lupus erythematosus responder index, Arthritis Care & Research, 61, 9, (1143-1151), (2009).
  Wiley Online Library
• Koichi Yanaba, Jean‐David Bouaziz, Takashi Matsushita, Cynthia M. Magro, E. William St.Clair and Thomas F. Tedder, B‐lymphocyte contributions to human autoimmune disease, Immunological Reviews, 223, 1, (284-299), (2008).
  Wiley Online Library
• Jean Sibilia and Jean-Louis Pasquali, Actualités et perspectives thérapeutiques du lupus systémique, La Presse Médicale, 10.1016/j.lpm.2007.11.011, 37, 3, (444-459), (2008).
  Crossref
• Nils Lonberg, Fully human antibodies from transgenic mouse and phage display platforms, Current Opinion in Immunology, 10.1016/j.coi.2008.06.004, 20, 4, (450-459), (2008).
  Crossref
• Jian Sun, Zhou Lin, Jiannan Feng, Yan Li and Beifen Shen, BAFF-targeting therapy, a promising strategy for treating autoimmune diseases, European Journal of Pharmacology, 10.1016/j.ejphar.2008.08.027, 597, 1-3, (1-5), (2008).
  Crossref
• Meng Cao, Peng Cao, Huaijiang Yan, Fang Ren, Wuguang Lu, Yunlong Hu and Shuangquan Zhang, Construction and characterization of an enhanced GFP-tagged anti-BAFF scFv antibody, Applied Microbiology and Biotechnology, 10.1007/s00253-008-1447-9, 79, 3, (423-431), (2008).
  Crossref
• Fang Ren, Bao-Cun Li, Na-Na Zhang, Meng Cao, Wen-Bing Dan and Shuang-Quan Zhang, Expression, purification and characterization of anti-BAFF antibody secreted from the yeast Pichia pastoris, Biotechnology Letters, 10.1007/s10529-008-9657-x, 30, 6, (1075-1080), (2008).
  Crossref
• Z. Amoura, J. Haroche and J.-C. Piette, Lupus systémique : les traitements du futur, La Revue de Médecine Interne, 10.1016/j.revmed.2008.02.013, 29, 9, (718-724), (2008).
  Crossref
• Anisur Rahman and David A. Isenberg, Systemic Lupus Erythematosus, New England Journal of Medicine, 10.1056/NEJMra071297, 358, 9, (929-939), (2008).
  Crossref
• Achim Rothe, Barbara E Power and Peter J Hudson, Therapeutic advances in rheumatology with the use of recombinant proteins, Nature Clinical Practice Rheumatology, 10.1038/ncprheum0909, 4, 11, (605-614), (2008).
  Crossref
• Katsuya Suzuki, Yumiko Setoyama, Keiko Yoshimoto, Kensei Tsuzaka, Tohru Abe and Tsutomu Takeuchi, Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells, Cytokine, 10.1016/j.cyto.2008.06.005, 44, 1, (44-48), (2008).
  Crossref
• R. T. Woodland, C. J. Fox, M. R. Schmidt, P. S. Hammerman, J. T. Opferman, S. J. Korsmeyer, D. M. Hilbert and C. B. Thompson, Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival, Blood, 10.1182/blood-2007-03-077222, 111, 2, (750-760), (2008).
  Crossref
• Changhai Ding, Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases, Expert Opinion on Biological Therapy, 10.1517/14712598.8.11.1805, 8, 11, (1805-1814), (2008).
  Crossref
• Hiroki Mitoma, Takahiko Horiuchi, Hiroshi Tsukamoto, Yasuhiro Tamimoto, Yasutaka Kimoto, Ayumi Uchino, Kentaro To, Shin‐Ichi Harashima, Nobuaki Hatta and Mine Harada, Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab, Arthritis & Rheumatism, 58, 5, (1248-1257), (2008).
  Wiley Online Library
• Miri Blank and Yehuda Shoenfeld, B cell targeted therapy in autoimmunity, Journal of Autoimmunity, 10.1016/j.jaut.2007.02.001, 28, 2-3, (62-68), (2007).
  Crossref
• Jiska M. Meijer, Justin Pijpe, Hendrika Bootsma, Arjan Vissink and Cees G. M. Kallenberg, The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome, Clinical Reviews in Allergy & Immunology, 10.1007/s12016-007-8005-6, 32, 3, (292-297), (2007).
  Crossref
• Adrienn Angyal, József Prechl and Gabriella Sármay, Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases, Expert Opinion on Biological Therapy, 10.1517/14712598.7.5.691, 7, 5, (691-704), (2007).
  Crossref
• Takashi Matsushita, Minoru Hasegawa, Yukiyo Matsushita, Takeshi Echigo, Takamasa Wayaku, Mayuka Horikawa, Fumihide Ogawa, Kazuhiko Takehara and Shinichi Sato, Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ‐specific autoimmune diseases, Experimental Dermatology, 16, 2, (87-93), (2006).
  Wiley Online Library
• Maria Dall'Era, Eliza Chakravarty, Daniel Wallace, Mark Genovese, Michael Weisman, Arthur Kavanaugh, Kenneth Kalunian, Patricia Dhar, Emmanuelle Vincent, Claudia Pena‐Rossi and David Wofsy, Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial, Arthritis & Rheumatism, 56, 12, (4142-4150), (2007).
  Wiley Online Library
• Menna R. Clatworthy and Kenneth G. C. Smith, B cells in glomerulonephritis: focus on lupus nephritis, Seminars in Immunopathology, 10.1007/s00281-007-0092-1, 29, 4, (337-353), (2007).
  Crossref
• Behrouz Nikbin, Mandana Mohyeddin Bonab, Farideh Khosravi and Fatemeh Talebian, Role of B Cells in Pathogenesis of Multiple Sclerosis, The Neurobiology of Multiple Sclerosis, 10.1016/S0074-7742(07)79002-5, (13-42), (2007).
  Crossref
• Steven P. Treon, Evdoxia Hatjiharissi, Xavier Leleu, Anne-Sophie Moreau, Aldo Roccaro, Zachary R. Hunter, Jacob D. Soumerai, Bryan Ciccarelli, Lian Xu, Antonio Sacco, Hai T. Ngo, Xiaoying Jia, Cao Yang, Sophia Adamia, Andrew R. Branagan, Allen W. Ho, Daniel D. Santos, Olivier Tournilhac, Robert J. Manning, Renee Leduc, Kelly O'Connor, Marybeth Nelson, Christopher J. Patterson and Irene Ghobrial, Novel Agents in the Treatment of Waldenström's Macroglobulinemia, Clinical Lymphoma and Myeloma, 10.3816/CLM.2007.s.023, 7, (S199-S206), (2007).
  Crossref
• Fabienne Mackay, Joanna R Groom and Stuart G Tangye, An important role for B-cell activation factor and B cells in the pathogenesis of Sj??gren??s syndrome, Current Opinion in Rheumatology, 10.1097/BOR.0b013e328277ef4c, 19, 5, (406-413), (2007).
  Crossref
• Tracy M. Frech and Daniel O. Clegg, The utility of nutraceuticals in the treatment of osteoarthritis, Current Rheumatology Reports, 10.1007/s11926-007-0018-x, 9, 1, (25-30), (2007).
  Crossref
• Takashi Matsushita, Manabu Fujimoto, Minoru Hasegawa, Yukiyo Matsushita, Kazuhiro Komura, Fumihide Ogawa, Rei Watanabe, Kazuhiko Takehara and Shinichi Sato, BAFF Antagonist Attenuates the Development of Skin Fibrosis in Tight-Skin Mice, Journal of Investigative Dermatology, 10.1038/sj.jid.5700919, 127, 12, (2772-2780), (2007).
  Crossref
• S. Bosello, J.-O. Pers, C. Rochas, V. Devauchelle, M. De Santis, C. Daridon, A. Saraux, G.F. Ferraccioli and P. Youinou, Baff and Rheumatic Autoimmune Disorders: Implications for Disease Management and Therapy, International Journal of Immunopathology and Pharmacology, 10.1177/039463200702000101, 20, 1, (1-8), (2016).
  Crossref
• Chris G. Mueller, Charlotte Boix, Wing‐Hong Kwan, Cécile Daussy, Emilie Fournier, Wolf H. Fridman and Thierry J. Molina, Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation, Journal of Leukocyte Biology, 82, 3, (567-575), (2007).
  Wiley Online Library
• A. Binard and P. Youinou, BAFF, A newcomer to the lupus party, Lupus, 10.1177/0961203307081512, 16, 9, (699-700), (2016).
  Crossref
• Huiguang Gao, Aina Bian, Yingru Zheng, Rongfen Li, Qing Ji, Gang Huang, Daqiang Hu, Li Zhang, Wei Gong, Ying Hu and Fengtian He, sBAFF mutants induce neutralizing antibodies against BAFF, FEBS Letters, 581, 4, (581-586), (2007).
  Wiley Online Library
• Maida WONG and And C. S. LAU, Management of systemic lupus erythematosus: a brief update on recent advances, APLAR Journal of Rheumatology, 9, 4, (387-391), (2006).
  Wiley Online Library
• E. William St.Clair and Thomas F. Tedder, New prospects for autoimmune disease therapy: B cells on deathwatch, Arthritis & Rheumatism, 54, 1, (1-9), (2005).
  Wiley Online Library
• David Isenberg and Anisur Rahman, Systemic lupus erythematosus—2005 annus mirabilis?, Nature Clinical Practice Rheumatology, 10.1038/ncprheum0116, 2, 3, (145-152), (2006).
  Crossref
• Stacey R. Dillon, Jane A. Gross, Stephen M. Ansell and Anne J. Novak, An APRIL to remember: novel TNF ligands as therapeutic targets, Nature Reviews Drug Discovery, 10.1038/nrd1982, 5, 3, (235-246), (2006).
  Crossref
• Paul Hasler and Moncef Zouali, B lymphocytes as therapeutic targets in systemic lupus erythematosus, Expert Opinion on Therapeutic Targets, 10.1517/14728222.10.6.803, 10, 6, (803-815), (2006).
  Crossref
• Andrew P.R. Sutherland, Fabienne Mackay and Charles R. Mackay, Targeting BAFF: Immunomodulation for autoimmune diseases and lymphomas, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2006.06.002, 112, 3, (774-786), (2006).
  Crossref
• Jean Sibilia, Les biothérapies immunomodulatrices: Une révolution thérapeutique dans les maladies auto-immunes, Revue Francophone des Laboratoires, 10.1016/S1773-035X(06)80321-7, 2006, 384, (34-39), (2006).
  Crossref
• Robert T. Woodland, Madelyn R. Schmidt and Craig B. Thompson, BLyS and B cell homeostasis, Seminars in Immunology, 10.1016/j.smim.2006.06.001, 18, 5, (318-326), (2006).
  Crossref
• Jonathan C. W. Edwards and Geraldine Cambridge, B-cell targeting in rheumatoid arthritis and other autoimmune diseases, Nature Reviews Immunology, 10.1038/nri1838, 6, 5, (394-403), (2006).
  Crossref
• William Stohl and R. John Looney, B cell depletion therapy in systemic rheumatic diseases: Different strokes for different folks?, Clinical Immunology, 10.1016/j.clim.2006.03.010, 121, 1, (1-12), (2006).
  Crossref
• Takashi Matsushita, Minoru Hasegawa, Koichi Yanaba, Masanari Kodera, Kazuhiko Takehara and Shinichi Sato, Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes, Arthritis & Rheumatism, 54, 1, (192-201), (2005).
  Wiley Online Library
• Stéphanie Haiat, Christian Billard, Claire Quiney, Florence Ajchenbaum‐Cymbalista and Jean‐Pierre Kolb, Role of BAFF and APRIL in human B‐cell chronic lymphocytic leukaemia, Immunology, 118, 3, (281-292), (2006).
  Wiley Online Library
• Z. Amoura and J.-C. Piette, Nouvelles approches thérapeutiques des maladies auto-immunes, Revue Neurologique, 10.1016/S0035-3787(06)75152-9, 162, (7-11), (2006).
  Crossref
• Paul Hasler, Biological therapies directed against cells in autoimmune disease, Springer Seminars in Immunopathology, 10.1007/s00281-006-0013-8, 27, 4, (443-456), (2006).
  Crossref
• Jean Sibilia, Treatment of systemic lupus erythematosus in 2006, Joint Bone Spine, 10.1016/j.jbspin.2006.09.003, 73, 6, (591-598), (2006).
  Crossref
• Wendy G. Halpern, Patrick Lappin, Thomas Zanardi, Wendy Cai, Marta Corcoran, John Zhong and Kevin P. Baker, Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects, Toxicological Sciences, 10.1093/toxsci/kfj148, 91, 2, (586-599), (2006).
  Crossref
• Peng Cao, Shuangquan Zhang, Zhunan Gong, Xiangming Tang, Meng Cao and Yunlong Hu, Development of a compact anti-BAFF antibody in Escherichia coli, Applied Microbiology and Biotechnology, 10.1007/s00253-006-0432-4, 73, 1, (151-157), (2006).
  Crossref
• Zahir Amoura and Jean-Charles Piette, Nouvelles approches thérapeutiques des maladies autoimmunes, La Presse Médicale, 10.1016/S0755-4982(06)74667-X, 35, 4, (709-713), (2006).
  Crossref
• G. Thom, A. C. Cockroft, A. G. Buchanan, C. Joberty Candotti, E. S. Cohen, D. Lowne, P. Monk, C. P. Shorrock-Hart, L. Jermutus and R. R. Minter, Probing a protein-protein interaction by in vitro evolution, Proceedings of the National Academy of Sciences, 10.1073/pnas.0602341103, 103, 20, (7619-7624), (2006).
  Crossref
• Jean Sibilia, Le traitement du lupus érythémateux systémique en 2006, Revue du Rhumatisme, 10.1016/j.rhum.2006.09.003, 73, 10-11, (977-984), (2006).
  Crossref
• Paul J. Carter, Potent antibody therapeutics by design, Nature Reviews Immunology, 10.1038/nri1837, 6, 5, (343-357), (2006).
  Crossref
• Maria Groves, Steven Lane, Julie Douthwaite, David Lowne, D. Gareth Rees, Bryan Edwards and Ronald H. Jackson, Affinity maturation of phage display antibody populations using ribosome display, Journal of Immunological Methods, 10.1016/j.jim.2006.04.002, 313, 1-2, (129-139), (2006).
  Crossref
• Yulia Vugmeyster, Dhaya Seshasayee, Wesley Chang, Anahid Storn, Kathy Howell, Susan Sa, Tenea Nelson, Flavius Martin, Iqbal Grewal, Ellen Gilkerson, Ben Wu, Jeff Thompson, Barbara N. Ehrenfels, Song Ren, An Song, Thomas R. Gelzleichter and Dimitry M. Danilenko, A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells and Lymphoid Tissue Marginal Zone and Follicular B Cells in Cynomolgus Monkeys, The American Journal of Pathology, 10.2353/ajpath.2006.050600, 168, 2, (476-489), (2006).
  Crossref
• Huiguang Gao, Weiling Fu, Rongfen Li, Linfeng Chen, Qing Ji, Li Zhang, Gang Huang and Fengtian He, Expression and purification of a soluble B lymphocyte stimulator mutant modified with the T-helper cell epitope, Biotechnology Letters, 10.1007/s10529-006-9139-y, 28, 20, (1649-1654), (2006).
  Crossref
• Flavius Martin and Andrew C. Chan, B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic, Annual Review of Immunology, 10.1146/annurev.immunol.24.021605.090517, 24, 1, (467-496), (2006).
  Crossref
• J.C.W. Edwards, G. Cambridge and M.J. Leandro, B cell depletion therapy in rheumatic disease, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2006.05.010, 20, 5, (915-928), (2006).
  Crossref
• Margrit Wiesendanger, Anfisa Stanevsky, Susan Kovsky and Betty Diamond, Novel therapeutics for systemic lupus erythematosus, Current Opinion in Rheumatology, 10.1097/01.bor.0000218941.04613.85, 18, 3, (227-235), (2006).
  Crossref
• Stuart G. Tangye, Vanessa L. Bryant, Amanda K. Cuss and Kim L. Good, BAFF, APRIL and human B cell disorders, Seminars in Immunology, 10.1016/j.smim.2006.04.004, 18, 5, (305-317), (2006).
  Crossref
• Marinos C. Dalakas, B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2006.03.005, 112, 1, (57-70), (2006).
  Crossref
• David Bannister, Andrew Wilson, Leah Prowse, Meg Walsh, Rob Holgate, Lutz Jermutus and Trevor Wilkinson, Parallel, high‐throughput purification of recombinant antibodies for in vivo cell assays, Biotechnology and Bioengineering, 94, 5, (931-937), (2006).
  Wiley Online Library
• Achim Rothe, Ralf J. Hosse and Barbara E. Power, In vitro display technologies reveal novel biopharmaceutics, The FASEB Journal, 20, 10, (1599), (2006).
  Crossref
• U Salzer, H M Chapel, A D B Webster, Q Pan-Hammarström, A Schmitt-Graeff, M Schlesier, H H Peter, J K Rockstroh, P Schneider, A A Schäffer, L Hammarström and B Grimbacher, Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans, Nature Genetics, 10.1038/ng1600, 37, 8, (820-828), (2005).
  Crossref
• Peng Cao, Zhinan Xia, Wei Song and Shuangquan Zhang, Neutralizing human anti-B-cell-activating factor of the TNF family (BAFF) scFv selected from phage antibody library, Immunology Letters, 10.1016/j.imlet.2005.05.001, 101, 1, (87-94), (2005).
  Crossref
• Flavius Martin and Vishva M Dixit, Unraveling TACIt functions, Nature Genetics, 10.1038/ng0805-793, 37, 8, (793-794), (2005).
  Crossref
• Hans H Peter and Klaus Warnatz, Molecules involved in T–B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity, Expert Opinion on Biological Therapy, 10.1517/14712598.5.1.S61, 5, sup1, (S61-S71), (2005).
  Crossref
• Maria AT Groves and Jane K Osbourn, Applications of ribosome display to antibody drug discovery, Expert Opinion on Biological Therapy, 10.1517/14712598.5.1.125, 5, 1, (125-135), (2005).
  Crossref
• Gisele Zandman-Goddard, Hedi Orbach and Yehuda Shoenfeld, Novel approaches to therapy for systemic lupus erythematosus: update 2005, Expert Review of Clinical Immunology, 10.1586/1744666X.1.2.223, 1, 2, (223-238), (2014).
  Crossref
• Takashi MATSUSHITA and Shinichi SATO, The role of BAFF in autoimmune diseases, Japanese Journal of Clinical Immunology, 10.2177/jsci.28.333, 28, 5, (333-342), (2005).
  Crossref
• P. Szodoray and R. Jonsson, The BAFF/APRIL System in Systemic Autoimmune Diseases with a Special Emphasis on Sjögren's Syndrome, Scandinavian Journal of Immunology, 62, 5, (421-428), (2005).
  Wiley Online Library
• Yulia Vugmeyster, Joseph Beyer, Kathy Howell, Dan Combs, Paul Fielder, Jihong Yang, Ferhan Qureshi, Bryan Sandlund, Ly Kawaguchi, Wolfgang Dummer, Henry Lowman and Kathleen McKeever, Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis, Journal of Immunotherapy, 10.1097/01.cji.0000155050.03916.04, 28, 3, (212-219), (2005).
  Crossref
• Jean Sibilia and Christelle Sordet, Immunothérapies du lupus systémique : innovations et perspectives, Revue du Rhumatisme, 10.1016/j.rhum.2004.12.014, 72, 6, (572-591), (2005).
  Crossref
• S Vasoo and G RV Hughes, Theory, targets and therapy in systemic lupus erythematosus, Lupus, 10.1191/0961203305lu2133oa, 14, 3, (181-188), (2016).
  Crossref
• J. C. W. Edwards and G. Cambridge, Prospects for B-cell-targeted therapy in autoimmune disease, Rheumatology, 10.1093/rheumatology/keh446, 44, 2, (151-156), (2004).
  Crossref
• Ulrich Salzer and Bodo Grimbacher, TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity?, Current Opinion in Allergy and Clinical Immunology, 10.1097/01.all.0000191887.89773.cc, 5, 6, (496-503), (2005).
  Crossref
• Yong Wook Park, Sergey Pryshchep, Thorsten M Seyler, Jörg J Goronzy and Cornelia M Weyand, B cells as a therapeutic target in autoimmune diseases, Expert Opinion on Therapeutic Targets, 10.1517/14728222.9.3.431, 9, 3, (431-445), (2005).
  Crossref
• J. Sibilia and C. Sordet, Le rituximab : une biothérapie originale dans les maladies auto-immunes, La Revue de Médecine Interne, 10.1016/j.revmed.2004.12.013, 26, 6, (485-500), (2005).
  Crossref
• D. Stichweh and V. Pascual, Lupus eritematoso sistémico pediátrico, Anales de Pediatría, 10.1157/13079833, 63, 4, (321-329), (2005).
  Crossref
• Henda Bouali and Gary Gilkeson, New therapies and preventive strategies to treat and minimize damage in lupus, Current Rheumatology Reports, 10.1007/s11926-005-0052-5, 7, 6, (457-462), (2005).
  Crossref
• Lai Guan Ng, Charles R. Mackay and Fabienne Mackay, The BAFF/APRIL system: life beyond B lymphocytes, Molecular Immunology, 10.1016/j.molimm.2004.06.041, 42, 7, (763-772), (2005).
  Crossref
• Mark C. Genovese, Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis, JCR: Journal of Clinical Rheumatology, 10.1097/01.rhu.0000166625.65114.5f, 11, Supplement, (S45-S54), (2005).
  Crossref
• Mathula Thangarajh, Andreia Gomes, Thomas Masterman, Jan Hillert and Peter Hjelmström, Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis, Journal of Neuroimmunology, 10.1016/j.jneuroim.2004.03.017, 152, 1-2, (183-190), (2004).
  Crossref
• Jean Sibilia, Novel concepts and treatments for autoimmune disease: ten focal points, Joint Bone Spine, 10.1016/j.jbspin.2004.04.007, 71, 6, (511-517), (2004).
  Crossref
• William Stohl, Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders, Expert Opinion on Therapeutic Targets, 10.1517/14728222.8.3.177, 8, 3, (177-189), (2005).
  Crossref
• Joan T. Merrill, Doruk Erkan and Jill P. Buyon, Challenges in bringing the bench to bedside in drug development for sle, Nature Reviews Drug Discovery, 10.1038/nrd1577, 3, 12, (1036-1046), (2004).
  Crossref
• Jean Sibilia, Nouveaux concepts et nouveaux traitements dans les maladies auto-immunes : les dix points d'actualité, Revue du Rhumatisme, 10.1016/j.rhum.2004.04.012, 71, 12, (1114-1121), (2004).
  Crossref
• Andrew P Cope and Marc Feldmann, Emerging approaches for the therapy of autoimmune and chronic inflammatory disease, Current Opinion in Immunology, 10.1016/j.coi.2004.09.005, 16, 6, (780-786), (2004).
  Crossref
• Prodromos I. Sidiropoulos, George K. Bertsias, Herakles D. Kritikos and Dimitrios T. Boumpas, Therapeutic strategies for refractory systemic lupus erythematosus, Drug Discovery Today: Therapeutic Strategies, 10.1016/j.ddstr.2004.11.011, 1, 3, (375-382), (2004).
  Crossref
• Kevin P Baker, BLyS—an essential survival factor for B cells: basic biology, links to pathology and therapeutic target, Autoimmunity Reviews, 10.1016/j.autrev.2004.02.001, 3, 5, (368-375), (2004).
  Crossref
• W Stohl, A therapeutic role for BLyS antagonists, Lupus, 10.1191/0961203304lu1019oa, 13, 5, (317-322), (2016).
  Crossref
• Flavius Martin and Andrew C Chan, Pathogenic Roles of B Cells in Human Autoimmunity, Immunity, 10.1016/S1074-7613(04)00112-8, 20, 5, (517-527), (2004).
  Crossref
• Gisele Zandman‐Goddard and Yehuda Shoenfeld, Therapy with biologic agents in SLE, APLAR Journal of Rheumatology, 7, 1, (79-82), (2004).
  Wiley Online Library
• William Stohl, Samy Metyas, Soon‐Min Tan, Gurtej S. Cheema, Bonifacia Oamar, Dong Xu, Viktor Roschke, Youmei Wu, Kevin P. Baker and David M. Hilbert, B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations, Arthritis & Rheumatism, 48, 12, (3475-3486), (2003).
  Wiley Online Library
• Justa Friebus-Kardash, Leonore Branco, Camillo Ribi, Carlo Chizzolini, Uyen Huynh-Do, Denise Dubler, Pascale Roux-Lombard, Sebastian Dolff, Andreas Kribben, Ute Eisenberger and Marten Trendelenburg, Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus, Nephrology Dialysis Transplantation, 10.1093/ndt/gfx220, (2017).
  Crossref
• William Stohl and David M Hilbert, The discovery and development of belimumab: the anti-BLyS–lupus connection, Nature Biotechnology, 10.1038/nbt.2076, 30, 1, (69-77), (2012)., (2012).
  Crossref
• Fabien B. Vincent, Eric F. Morand, Pascal Schneider and Fabienne Mackay, The BAFF/APRIL system in SLE pathogenesis, Nature Reviews Rheumatology, 10.1038/nrrheum.2014.33, 10, 6, (365-373), (2014)., (2014).
  Crossref
• Ghada Alsaleh, Antoine François, Lucas Philippe, Ya-Zhuo Gong, Seiamak Bahram, Semih Cetin, Sébastien Pfeffer, Jacques-Eric Gottenberg, Dominique Wachsmann, Philippe Georgel, Jean Sibilia and Shervin Assassi, MiR-30a-3p Negatively Regulates BAFF Synthesis in Systemic Sclerosis and Rheumatoid Arthritis Fibroblasts, PLoS ONE, 10.1371/journal.pone.0111266, 9, 10, (e111266), (2014).
  Crossref
• Herbert Struemper, Mita Thapar and David Roth, Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus, Clinical Pharmacokinetics, 10.1007/s40262-017-0586-5, (2017).
  Crossref
• Y H Lee and G G Song, Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials, Lupus, 10.1177/0961203317713143, (096120331771314), (2017).
  Crossref
• Domagoj Vucic, Vishva M. Dixit and Ingrid E. Wertz, Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death, Nature Reviews Molecular Cell Biology, 10.1038/nrm3143, 12, 7, (439-452), (2011).
  Crossref
• Wen Xiong and Robert G. Lahita, Pragmatic approaches to therapy for systemic lupus erythematosus, Nature Reviews Rheumatology, 10.1038/nrrheum.2013.157, 10, 2, (97-107), (2013)., (2013).
  Crossref